Hepatic recompensation in patients with decompensated cirrhosis – What is new?

Hepatic recompensation in patients with decompensated cirrhosis has emerged as a transformative concept in liver disease management, challenging the long-held belief that cirrhosis is irreversible. Recent advancements have expanded our understanding of recompensation, defined by the Baveno VII consensus as control or cure of the underlying cause, resolution of ascites and encephalopathy without medication, no variceal bleeding for 12 months, and restoration of liver function to Child-Turcotte-Pugh (CTP) class A. Here's what's new in this field:

---

### **1. Paradigm Shift: Reversibility of Cirrhosis**

Cirrhosis, once deemed a permanent condition, is now understood to be reversible in certain cases if the underlying causal factors are effectively managed. This shift has been driven by interventions targeting viral hepatitis, alcohol use disorder, autoimmune diseases, and metabolic dysfunction-associated liver disease (MASLD, formerly NAFLD).

---

### **2. Advances in Management of Underlying Causes**

Recompensation is most achievable in cirrhosis caused by hepatitis C virus (HCV), hepatitis B virus (HBV), and alcohol-related liver disease. Emerging evidence also suggests the possibility of recompensation in MASLD, autoimmune liver diseases, primary biliary cholangitis (PBC), and Wilson’s disease.

#### **HCV:**

• Direct-acting antivirals (DAAs) have revolutionized HCV treatment, achieving sustained virological response (SVR) in 80–90% of decompensated patients.
• Approximately 25% of patients meet Baveno VII recompensation criteria post-treatment, with improved MELD/CTP scores and reduced complications.
• However, the risk of hepatocellular carcinoma (HCC) persists, necessitating ongoing surveillance.

#### **HBV:**

• Long-term nucleos(t)ide analogue therapy (e.g., entecavir, tenofovir) improves survival and reduces decompensation events in HBV-related cirrhosis.
• Over 50% of patients in some cohorts achieve recompensation, demonstrating the effectiveness of antiviral therapy.

#### **Alcohol-Associated Cirrhosis:**

• Studies show that 8–18% of decompensated patients achieve recompensation with sustained abstinence.
• Predictors of recompensation include lower baseline MELD scores, lower hepatic venous pressure gradient (HVPG), higher albumin levels, and female sex.
• Relapse prevention remains critical to maintaining recompensation.

#### **MASLD and Obesity:**

• Although no standard drug therapy exists, weight loss (via lifestyle modifications or bariatric surgery in selected patients) has shown promise in improving liver function.
• Early reports suggest that recompensation may be possible in MASLD-related cirrhosis, though further research is needed.

#### **Autoimmune Liver Diseases and PBC:**

• Small studies indicate that immunosuppressive therapy in autoimmune hepatitis and ursodeoxycholic acid (UDCA) in PBC can lead to recompensation.
• However, progression and relapse remain common, and lifelong HCC surveillance is recommended.

---

### **3. Biological Mechanisms of Recompensation**

Recompensation is driven by several biological processes, including:

• **Collagen degradation and fibrosis regression:** Reduction of scar tissue improves liver architecture and function.
• **Vascular remodeling:** Decreased portal hypertension reduces complications like ascites and variceal bleeding.
• **Reduced hepatic inflammation:** Suppression of inflammatory pathways contributes to improved liver function.

---

### **4. Role of TIPS (Transjugular Intrahepatic Portosystemic Shunt)**

TIPS placement can control portal hypertension, ascites, and variceal bleeding. Approximately 24% of decompensated patients achieve recompensation post-TIPS, though it remains unclear whether the benefit is primarily due to TIPS itself or effective management of the underlying disease.

---

### **5. Predictive Models for Recompensation**

Emerging predictive tools combine clinical and biochemical factors to estimate the likelihood of recompensation:

• **BE3A (for HCV):** Incorporates bilirubin, albumin, and INR.
• **BC2AID and Brec-PAS (for HBV):** Include bilirubin, albumin, INR, BMI, and complications.

These models are promising but not yet widely adopted in clinical practice.

---

### **6. Persistent Portal Hypertension**

Even after recompensation, portal hypertension may persist, requiring continued management:

• HVPG reductions are not always accompanied by variceal regression, necessitating surveillance and beta-blocker use.
• Non-selective beta-blockers should not be discontinued unless HVPG falls below 10 mmHg due to ongoing risk of rebleeding and decompensation.

---

### **7. Hepatocellular Carcinoma (HCC) Risk**

Recompensation lowers but does not eliminate HCC risk:

• Annual HCC incidence rates remain at 1–3% in recompensated HBV and HCV cirrhosis patients.
• Lifelong surveillance is essential, even for patients with functional recovery.

---

### **8. Transplant Delisting**

Recompensation can lead to delisting from liver transplant waitlists:

• Reports show that 6–10% of patients, particularly those with HBV, HCV, or alcohol-related cirrhosis, can be safely delisted due to clinical improvement.
• This has significant implications for organ allocation and resource utilization.

---

### **9. Outcomes Compared to Compensated Cirrhosis**

Recompensated patients achieve survival rates closer to those with compensated cirrhosis. However, they remain at higher risk of HCC and certain complications, necessitating ongoing monitoring and care.

---

### **10. Limitations of Current Criteria**

The Baveno VII criteria for recompensation exclude patients on diuretics or prophylactic lactulose, potentially underestimating real-world recompensation rates. Many clinically improved patients remain on supportive medications, highlighting the need for more inclusive definitions.

---

### **11. Research Gaps and Future Directions**

• **Mechanisms and Durability:** More prospective studies are needed to define the biological mechanisms, timelines, and long-term durability of recompensation.
• **Biomarkers:** Current markers like MELD and CTP scores have limitations. Non-invasive biomarkers and machine learning models may improve patient selection and outcome prediction.
• **Emerging Therapies:** Novel treatments targeting fibrosis regression, portal hypertension, and the gut-liver axis are under investigation.

---

### **12. Public Health Implications**

Efforts to reduce alcohol consumption, eliminate viral hepatitis, and manage obesity could significantly increase recompensation rates, reduce liver transplant needs, and improve outcomes, especially in resource-limited settings.

---

### **Conclusion**

The concept of hepatic recompensation represents a major advancement in the management of decompensated cirrhosis. While significant progress has been made in understanding its mechanisms and predictors, challenges remain in optimizing patient selection, improving long-term outcomes, and addressing persistent risks like portal hypertension and HCC. Ongoing research and public health initiatives hold promise for expanding the reach and impact of recompensation in cirrhosis care.